Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Intervalo de año de publicación
1.
PLoS One ; 19(4): e0301707, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38662709

RESUMEN

BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of childbearing age, associated with increased incidence of emotional disorders, anxiety and depression. OBJECTIVE: The aim was of this study was to investigate whether those women reporting PCOS differed to women without PCOS in measures of psychological well-being including body-image satisfaction and self-esteem across a Middle Eastern population. MATERIALS AND METHODS: An online survey link of 21 questions was shared and distributed across social media platforms (Instagram and WhatsApp). The main outcome measured was levels of self-esteem and body image satisfaction in association with symptoms experienced by the participants. RESULTS: 12,199 female subjects completed the survey of whom 3,329 respondents (27.3%) self-reported a diagnosis of PCOS. PCOS respondents felt less attractive compared to non-PCOS respondents (73.9% vs 80.5%, p<0.0001). More respondents with PCOS reported avoidance of their reflection in the mirror (61.7% vs 49.8%, p<0.001) and avoidance of social interactions (22.3% vs 32.3%, p<0.0001). More PCOS respondents wanted to lose weight (75.2% vs 68.5%, p<0.001) with increasing weight being associated with being less attractive (p<0.001). Fewer PCOS respondents felt satisfied/confident compared non-PCOS respondents (38.6% vs 50.7%, p<0.001). CONCLUSION: PCOS respondents reported significantly lower measures of self-esteem and body image satisfaction compared to non-PCOS respondents in this population.


Asunto(s)
Imagen Corporal , Síndrome del Ovario Poliquístico , Autoimagen , Medios de Comunicación Sociales , Humanos , Femenino , Síndrome del Ovario Poliquístico/psicología , Síndrome del Ovario Poliquístico/epidemiología , Adulto , Imagen Corporal/psicología , Estudios Transversales , Adulto Joven , Satisfacción Personal , Medio Oriente/epidemiología , Adolescente , Encuestas y Cuestionarios
2.
J Clin Endocrinol Metab ; 108(6): 1425-1431, 2023 05 17.
Artículo en Inglés | MEDLINE | ID: mdl-36510395

RESUMEN

CONTEXT: Total pancreatectomy with islet autotransplantation (TPIAT) is a definitive management for intractable pain in patients with chronic pancreatitis (CP). Islet autotransplantation (IAT) allows for the preservation of beta cells to prevent complications of long-term diabetes. OBJECTIVE: Our study follows TPIAT recipients for up to 12 years to determine the efficacy of the procedure completed with an off-site islet isolation facility. METHODS: Patient demographics, mixed meal tolerance test measures, glycosylated hemoglobin, insulin requirements, and homeostatic model assessment for insulin resistance values were collected prior to surgery and at the most recent follow-up assessment. RESULTS: Forty-four patients (median age, 46.0 years; range, 20-78 years) underwent TPIAT for CP. At an overall median follow-up time of 845.5 days (range, 195-4470 days) 8 patients were insulin independent and 36 patients were insulin dependent. At the most recent follow-up time point, islet yield per kilogram was the strongest indicator of insulin independence. Homeostatic model assessment for insulin resistance values were comparable between insulin independent and dependent cohorts. CONCLUSIONS: Our long-term follow-up data suggest that IAT can effectively reduce insulin requirements and improve postoperative glycemic control.


Asunto(s)
Resistencia a la Insulina , Trasplante de Islotes Pancreáticos , Islotes Pancreáticos , Pancreatitis Crónica , Humanos , Persona de Mediana Edad , Pancreatectomía/métodos , Trasplante Autólogo , Estudios de Seguimiento , Trasplante de Islotes Pancreáticos/métodos , Insulina , Pancreatitis Crónica/cirugía , Pancreatitis Crónica/complicaciones , Resultado del Tratamiento
3.
Cell Transplant ; 30: 9636897211057440, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34757864

RESUMEN

The inflammatory response is an obstacle to success in both allogeneic and autologous islet transplantation. In autologous islet transplantation (AIT), however, the recipient is also the donor, permitting pretreatment of donor/recipient for a controlled duration prior to transplantation. We sought to exploit this feature of (AIT) by pretreating donor/recipients with chronic pancreatitis undergoing total pancreatectomy and autologous islet transplantation (TPAIT) to test the hypothesis that peri-transplant treatment with the FDA-approved anti-inflammatory hydroxychloroquine (HCQ) improves graft function. In this randomized placebo-controlled pilot clinical study, patients (n = 6) were treated with oral HCQ for 30 days prior to and 90 days after TPAIT. In vivo islet function was assessed via Mixed Meal Tolerance Testing before HCQ treatment, 6- and 12-months after surgery. In vitro islet bioenergetics were assessed at the time of transplantation via extracellular flux analysis of islet preparation samples from the clinical trial cohort and six additional patients (n = 12). Our study shows that HCQ did not alter clinical endpoints, but HCQ-treated patients showed greater spare respiratory capacity (SRC) compared to samples from control patients (P=0.028). Glycolytic metabolism of islet preparations directly correlated with stimulated C-peptide secretion both before and after TPAIT (P=0.01, R2=0.489 and P=0.03, R2=0.674, respectively), and predicted in vivo islet function better than mitochondrial metabolism of islet preps or islet equivalents infused. Overnight culture of islet preparations altered bioenergetic function, significantly decreasing SRC and maximal respiration (P<0.001). In conclusion, while HCQ did not alter clinical outcomes, it was associated with significantly increased SRC in islet preparations. Bioenergetic analyses of islet preparations suggests that culture should be avoided and that glycolysis may be a more sensitive indicator of in vivo islet function than current metrics, including islet oxygen consumption and islet equivalents infused.


Asunto(s)
Metabolismo Energético/inmunología , Inhibidores Enzimáticos/uso terapéutico , Hidroxicloroquina/uso terapéutico , Trasplante de Islotes Pancreáticos/métodos , Trasplante Autólogo/métodos , Ensayos Clínicos como Asunto , Inhibidores Enzimáticos/farmacología , Femenino , Humanos , Hidroxicloroquina/farmacología , Masculino , Proyectos Piloto , Resultado del Tratamiento
4.
Case Rep Neurol Med ; 2021: 9917673, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34350042

RESUMEN

Dermoid cysts account for only a small fraction of intracranial masses, with extradural dermoid cysts being considered a much rarer entity than those located intradurally. Intracranial dermoid cysts vary in clinical presentations: some maybe asymptomatic whilst others harbor features of raised intracranial pressure, neurological deficits, or even aseptic meningitis. Dermoid cysts may also present with cutaneous lesions. Herein, we report a rare case of a 1-year-old female presenting with a midline, scalp abscess. Brain MRI revealed an intracranial, extradural tumor, with features suggestive of a dermoid cyst, unusually located in the crista galli, and complicated by the formation of two cutaneous sinus tracts. After identification and characterization by MRI, bitemporal craniotomy was performed with complete excision of the mass and sinus tracts. Histological analysis confirmed dermoid cyst as the final diagnosis. Postoperatively, the patient recovered fully and had no evidence of recurrence in subsequent visits. The case mentioned above highlights the rarity of such a presentation for an intracranial extradural dermoid cyst and the vitality of early imaging for midline cutaneous lesions for identification of intracranial extensions and avoidance of detrimental consequences.

5.
Expert Rev Clin Pharmacol ; 9(1): 27-34, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26512740

RESUMEN

Naltrexone-bupropion is a recently approved drug combination for chronic weight management. In this article, we discuss the rationale for its use as a combination followed by a comprehensive review of safety and efficacy data from major preclinical, phase II and III clinical trials.


Asunto(s)
Fármacos Antiobesidad/uso terapéutico , Bupropión/uso terapéutico , Naltrexona/uso terapéutico , Obesidad/tratamiento farmacológico , Animales , Fármacos Antiobesidad/administración & dosificación , Fármacos Antiobesidad/efectos adversos , Bupropión/administración & dosificación , Bupropión/efectos adversos , Preparaciones de Acción Retardada , Aprobación de Drogas , Combinación de Medicamentos , Humanos , Naltrexona/administración & dosificación , Naltrexona/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA